It has recently been reported that depletion of B-family DNA polymerases, which includes POLE2, together with CHK1 pharmacological inhibition is a synthetically lethal combination in human colorectal cancer cells, which opens a promising window of opportunity for the treatment of POLE2-derived tumors [76]. The gene discussed is POLE2; the disease is colorectal cancer.